trending Market Intelligence /marketintelligence/en/news-insights/trending/tjjlhetd66qrs8ppwyujqg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Brazil Pay TV Down Record Amount In 2019, With Losses Continuing In Q1'20

Case Study: Transforming Sales Enablement Data at a Global Advertising and Media Firm

Impact of COVID 19 on US Video Entertainment Trends

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19


Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Calithera BioSciences Inc. is partnering with Bristol-Myers Squibb Co. to determine whether its CB-839 drug can be combined with Opdivo to treat kidney cancer.

Bristol-Myers' Opdivo is already approved as a treatment for certain types of cancer. CB-839 is currently in phase 1/2 clinical studies involving patients with clear cell renal cell carcinoma.